The dramatic rise in the prevalence of antibiotic-resistant Streptococcus pneumoniae has prompted national recommendations for routine surveillance of invasive pneumococcal infections. 1 Ideally, surveillance data would be shared with clinicians and used to promote judicious use of antibiotics. 2 Laboratory-based, mandated reporting of pneumococcal cases has been endorsed; however, implementation has been slow. 3 Possible reasons for the delay are staffing constraints and lengthy requirements for adding a reportable condition to state regulations. [4] [5] [6] As an alternative to statewide mandatory reporting, we developed an Antimicrobial Resistance Sentinel Network (ARSN) and assessed the utility of targeted surveillance in population centers, evaluated current laboratory susceptibility testing practices, and obtained a baseline of pneumococcal resistance in Washington State for use in a statewide campaign promoting the judicious use of antibiotics.
Methods
Using hospital utilization data collected by the Washington State Department of Health, we identified 3 distinct patient catchment regions of the state. These regions represented 70% of the population of Washington State and included all tertiary pediatric centers and all facilities with more than 375 beds. Letters requesting participation in ARSN were sent to infection-control staff at all hospitals in the selected regions. The network was initiated by the department of health to monitor antimicrobial resistance and to help formulate control measures.
Infection control practitioners at participating hospitals identified S. pneumoniae isolated from either blood or cerebrospinal fluid that was submitted to their laboratories between July 1, 1997 and June 30, 1998. For each isolate, microbiologic and patient demographic information was collected and submitted once each quarter to the department of health on a paper form. Information included age, sex, date of specimen collection, site of collection, antibiotics tested, methods used (i.e., disk diffusion, agar dilution, antimicrobial gradient strips, or broth dilution), numeric results, and interpretations of minimum inhibitory concentration (MIC) testing. Duplicate reports were not included in the analysis.
A case of invasive pneumococcal disease was defined as illness in a patient in whom S. pneumoniae was isolated from blood or cerebrospinal fluid. Antimicrobial susceptibility interpretive standards defined by the National Committee for Clinical Laboratory Standards (NCCLS) were used as breakpoints to classify isolates as susceptible (S), intermediate (I), or resistant (R). 7, 8 For penicillin, the MIC breakpoints were S ≤0.06 µg/mL, I = 0.12-1.0 µg/ mL, and R≥2.0 µg/mL. For extended-spectrum cephalosporins such as cefotaxime or ceftriaxone, the MIC breakpoints were S≤0.5 µg/ mL, I=1 µg/mL, and R≥2.0 µg/mL. For oxacillin disk diffusion, interpretation of zone diameters was S ≥ 20 mm and nonsusceptible (NS)<20 mm. Isolates that were oxacillin nonsusceptible were also considered penicillin nonsusceptible (i.e., penicillin intermediate and penicillin resistant combined) as described by the NCCLS.
We did not collect information on isolates other than blood and cerebrospinal fluid, because (1) collection of noninvasive isolates (e.g., sputum, ear swabs, tympanocenteses) varies by provider more than collection of blood and cerebrospinal fluid isolates; (2) respiratory isolates are often collected because of treatment failure and thus are more likely to be resistant; and (3) We calculated percentages for isolates nonsusceptible to penicillin by using the number in the adjacent column for each characteristic. c P = .003 when compared with all other ages.
ial Core Surveillance (EIP ABCs) are from blood and cerebrospinal fluid).
9,10
We sent letters to network participants each quarter to encourage the submission of case reports. Informational materials were sent quarterly and included interim summaries of the data submitted to the Department of Health, newsletters, pamphlets for distribution to patients, and recent journal articles on antibiotic resistance and methods promoting the judicious use of antibiotics. We also sent short descriptions of appropriate methods for pneumococcal susceptibility testing as determined by the NCCLS. After the first year of collection, a set of charts and graphs was sent to participants to summarize the findings. These were made available to participating infectioncontrol staff for presenting the network surveillance data at their hospitals.
Results
Between July 1, 1997 and June 30, 1998, 300 cases of invasive pneumococcal infection were reported from 27 hospitals participating in the surveillance network ( Table 1 ). The patients ranged in age from 1 week to 99 years (mean= 42 years). The majority of patients (54%) were younger than 2 years or older than 65 years; 53% were men. Most isolates were from blood (285; 95%). Ethnicity and race were provided infrequently on case reports. Most cases were from the Puget Sound region (169; 56%).
Isolates from 67 (22%) of the 300 patients were penicillin nonsusceptible. Only 191 (64%) of the isolates had MIC results reported for both penicillin and an extended-spectrum cephalosporin, as determined by the appropriate methods recommended by the NCCLS. Of the 191 isolates, 13.1% were penicillin intermediate and 10.5% were penicillin resistant, for a total of 23.6% nonsusceptible to penicillin ( Figure 1) ; 3.7% were extended-spectrum cephalosporin intermediate and 6.8% were extended-spectrum cephalosporin resistant, for a total of 10.5% nonsusceptible to an extendedspectrum cephalosporin. No isolates were resistant to vancomycin. Isolates that were resistant to an extended-spectrum cephalosporin were also frequently resistant to erythromycin and trimethoprim/sulfamethoxazole; however, most laboratories did not test against all these agents. Decreased susceptibility to penicillin was evident in isolates from both children and adults; however, children younger than 2 years were more likely to have infection with pneumococci nonsusceptible to penicillin (P=.003). We found no statistically significant differences in resistance when comparing the 3 ARSN regions (Table 1) .
To determine whether ARSN findings were comparable to other recent surveillance data, we compared our findings with those from 8 other sites in North America-including Oregon-participating in the CDC EIP ABCs (total population base = 19.8 million) (Paul Cieslak, MD, MPH, Oregon Health Division, Portland; Cynthia Whitney, MD, MPH, National Center for Infectious Diseases, CDC, Atlanta, Ga; written communications, September 1998). The prevalence of penicillinresistant pneumococci in Washington was not significantly different from that in Oregon (P= .85) or from national estimates (P=.13); however, national estimates were higher (Figure 1 ).
Within the 3 regions selected for surveillance, the 27 hospitals participating in ARSN represented 56% of all hospitals and 74% of all hospital beds. Most hospitals were in western Washington, around the Puget Sound. All major pediatric hospitals participated. Although all isolates were tested with either penicillin or oxacillin, 109 (36%) were not tested for MICs with both penicillin and an extendedspectrum cephalosporin immediately after the initial isolation of pneumococci in the blood and cerebrospinal fluid as recommended by the NCCLS. As the year progressed, the number of isolates that were inadequately tested declined from 75 of 166 (45%) in the first 6 months to 34 of 134 (25%) in the second 6 months (P<.001).
Discussion
Mandated, statewide, laboratory-based reporting of invasive pneumococcal infections has been recommended since 1995 as part of a strategy to minimize the impact of resistant pneumococci. 11, 12 Although many state health officials believe that more attention should be focused on antibiotic-resistant diseases, staffing constraints and complicated regulatory requirements have hindered implementation of surveillance for resistant infections. [4] [5] [6] We used a sentinel network of hospitals in Washington State to estimate the prevalence of antimicrobial-resistant pneumococci and found that 22% of all isolates had diminished susceptibility to penicillin; nearly 11% of those tested by penicillin MIC methods were fully resistant.
We compared ARSN findings with findings from a previous study in Washington that collected 275 pneumococcal isolates from patients with invasive disease. 13 The prevalence of penicillin-resistant pneumococci was significantly higher for the cases in ARSN (10.5%; collected 1997-1998) than for those in the previous study (1.5%; collected 1995-1996) (P < .001). Although differences exist between the 2 surveillance systems, the level of resistance in ARSN was significantly higher than that found in the earlier Washington study, suggesting that a possible rapid increase had occurred. Our findings were collected from a limited number of hospitals in selected sentinel regions but were similar to the more resource-intensive, statewide, active surveil- lance data from Oregon for the same time period (10.5% vs 11%). We selected sentinel regions and encouraged participation among the hospitals within each region rather than selecting 1 or 2 sentinel hospitals in many different regions. We found a number of potential benefits to this sentinel approach for monitoring resistance. First, the network allowed for data to be collected while revisions to the state reporting requirements were made. Second, the limited design of the network allowed for a simpler, more rapid collection of information. These data were available and valuable for a statewide campaign promoting the judicious use of antibiotics begun in the fall of 1998. Third, feedback was targeted to infection-control staff, who could then further disseminate the educational materials.
Fourth, feedback on susceptibility testing procedures recommended by the NCCLS probably contributed to improved testing over the first year of data collection. Heightened awareness of resistant pneumococcal isolates in hospital laboratories also led to an investigation of a cluster of multiresistant pneumococcal infections, with subsequent recommendations to improve the pneumococcal vaccination of elderly patients.
14 Fifth, our findings were similar to those collected through comprehensive, active surveillance in Oregon, a state with racial, socioeconomic, and geographic characteristics similar to those of Washington. This suggests that limited, general trends may be measured adequately by a scaled-down approach. Finally, the network is not limited to invasive pneumococcal illness and has the flexibility to be modified for monitoring other emerging resistance problems in the future.
The network approach also has limitations. First, we did not collect or test pneumococcal isolates and therefore relied on testing capabilities in participating laboratories. We identified inappropriate methods and provided information to improve testing; however, we were limited to 191 (64%) isolates for determining the combined prevalence of penicillin and extended-spectrum cephalosporin resistance. Second, because isolates were not collected, we were not able to have serotyping performed. This activity, while costly, may be beneficial as new pneumococcal vaccines are introduced for use in infants and children in the next few years.
Third, in Washington, as in other states, collection of surveillance data is primarily done by the county department of health. Use of the network shifted the duty of data aggregation and the development of valuable materials for provider feedback to the state department of health. Although the overall burden of a mandated approach is lessened with the network, a few dedicated health department staff are required for effective implementation. Finally, we did not perform active surveillance concomitantly in ARSN regions, and therefore we were not able to assess the validity of our findings in comparison with active surveillance findings in Washington. Further evaluation of the sentinel region approach may be needed before broader application of the method.
Surveillance for antibiotic-resistant S. pneumoniae can provide data valuable for promoting the judicious use of antibiotics. For states that face delays in implementing surveillance or that choose not to mandate reporting cases of invasive pneumococcal disease, a sentinel network approach may be an acceptable option for limited monitoring of antibiotic resistance trends.
Contributors
D. B. Jernigan planned the study, analyzed the data, and was the primary author of the paper. L. Kargacin and A. Poole contributed to the study design, data collection, data entry, and writing of the paper. J. Kobayashi supervised data analysis and contributed to the writing of the paper.
